Phaseline

Companies › Faron Pharmaceuticals

Faron Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
bexmarilimab–Phase 2Higher Risk Myelodysplastic Syndromes; Acute Myeloid Leukemia; Soft Tissue Sarcoma (STS); Melanoma (Skin Cancer)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05428969bexmarilimabPhase 1Acute Myeloid LeukemiaOncologyMar 2027
NCT07672769bexmarilimabPhase 2Higher Risk Myelodysplastic SyndromesOncologyNov 2027
NCT07460986bexmarilimabPhase 1Soft Tissue Sarcoma (STS)OncologyJul 2028
NCT07718243bexmarilimabPhase 1Melanoma (Skin Cancer)OncologyJan 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.